Expression Of S Baff, R Baff, And B Cells (Cd19+) As Potential Biomarker In Predicting Respons Treatment After Pulse Dose Metyl Prednisolone In Severe Sistemic Lupus Erithematosus
Main Article Content
Keywords
sBAFF, BAFF R, B cells (CD19), pulse dose, methyl prednisolone, predictors, biomarker, treatment response
Abstract
Background: B cell Activating Factors (BAFF) is a co stimulatory molecule that has become the target of recent SLE treatment. Pulse dose metyl prednisolone (MEP)has been widely used and is a standard protocol in management of severe and life threathening flare up. The aim of this study is to identify whethersoluble (S) BAFF along with its receptor,(R) BAFF and B Cells (CD19+) can become predictors of pulse dose metyl prednisolone (MEP) response treatment.
Method: Eighty subjects had been enrolled to this study. All subjects had SLE Disease Activity Index Score 2000 (SLEDAI 2K) score 12 or Lupus Nephritis Class 3 or 4 (WHO criteria) and decided to get pulse dose MEP. Prospective cohort study was conducted. All data as listed in SLEDAI 2k form were recorded before and after treatment. Enzyme-linked Immunoabsorbent Assay (ELISA) was used to measure S BAFF. Flowcytometry was used to measure BAFF Rand B cells (CD19+). Respons treatment was measured by SLEDAI 2K Responder Index (SRI) 50. Logistic Regression Analysis was used to identify the independent predictive factors for treatment response. Receiver Operating Characteristic (ROC) curve was used to find cut off point and Chi-sqare test to analyse proportion
difference and Relative Risk (RR) to treatment response
Results: There were 80 subjects enrolled in this study, all with high disease activity (mean SLEDAI 2k 30.04 ±10.8).The differerence of SLEDAI 2K score before and after pulse dose MEP was 36%. SLEDAI 2K post MEP pulse > 36% of SLEDAI 2K pre treatment was considered SRI 36 Responder (SRI-36 R). SLEDAI 2K post pulse dose MEP < 36 % of SLEDAI 2K pre treatment was consider SRI -36 Non Responde (NR). Soluble BAFF 2459,47 pg/ml, R BAFF > 2817 MFI , and B cells (CD 19)> 29,2% have OR0.36; 2.17, and 2.16respectively but not statistically significant (p>0,05). Only R BAFF > 59,1 % have OR4.84with p value 0,03095% CI, in predicting SRI-36NR.
Conclusions: BAFF R> 59,1% is a biomarker predictor of SRI-36 NR in pulse dose MEP with OR4,84, p value 0,030(95%CI).
References
2. Carter, R. H. et al. (2005) ‘Expression and occupancy of BAFF-R on B cells in systemic lupus erythematosus’, Arthritis and Rheumatism,
52(12), pp. 3943–3954.
3. Duan, J. H. et al. (2016) ‘Expression of BAFF and BR3 in patients with systemic lupus erythematosus’, Brazilian Journal of Medical and
Biological Research, 49(3), pp. 3–7.
4. Funauchi, M. and Yamagata, T. (2004) ‘Systemic lupus erythematosus’, Nippon rinsho. Japanese journal of clinical medicine, 62 Suppl 5, pp. 559–562.
5. Petri, M. A. et al. (2013) ‘Baseline predictors of systemic lupus erythematosus flares: Data from the combined placebo groups in the phase III belimumab trials’, Arthritis and Rheumatism, 65(8), pp. 2143–2153.
6. Ramanujam, M. and Davidson, A. (2004) ‘The current status of targeting BAFF/BLyS for autoimmune diseases’, Arthritis Research and
Therapy, 6(5), pp. 197–202.
7. Sellam, J. et al. (2007) ‘Decreased B cell activating factor receptor expression onperipheral lymphocytes associated with increased disease activity in primary Sjögren’s syndrome and systemic lupus erythematosus’, Annals of the Rheumatic Diseases, 66(6), pp. 790–797.
8. Stohl, W. (2017) ‘Inhibition of B cell activating factor (BAFF) in the management of systemic lupus erythematosus (SLE)’, Expert Review of
Clinical Immunology, 13(6), pp. 623–633.
9. Touma, Z., Gladman, D. D. and Urowitz, M. B. (2013) ‘Clinical Measures, Metrics, and Indices’, in Dubois’ Lupus Erythematosus and Related
Syndromes: Eighth Edition. Eighth Edi. Elsevier Inc., pp. 563–581.
10. Tsai, Y. et al. (2014) ‘CD8 + Treg Cells Associated with Decreasing Disease Activity after Intravenous Methylprednisolone Pulse
Therapy in Lupus Nephritis with Heavy Proteinuria’, PLoS ONE, 9(1), pp. 1–12.
11. Zaki, D. S. D. et al. (2019) ‘Study of B Cell Activating Factor ( BAFF ) and BAFF-R in Systemic Lupus Erythematosus Patients’, 9(6),
pp. 203–209.
12. Cathcart, E. S., Idelson, B. A., Scheinberg, M. A., & Couser, W. G. (1976). Beneficial effects of methylprednisolone “pulse” therapy in diffuse
proliferative lupus nephritis. Lancet (London, England), 1(7952), 163–166. https://doi.org/10.1016/s0140-6736(76)91272-1
13. Isenberg, D. A., Morrow, W. J., & Snaith, M. L. (1982). Methyl prednisolone pulse therapy in the treatment of systemic lupus erythematosus.
Annals of the Rheumatic Diseases, 41(4), 347–351. https://doi.org/10.1136/ard.41.4.347
14. Badsha, H., & Edwards, C. J. (2003). Intravenous pulses of methylprednisolone for systemic lupus erythematosus. Seminars in Arthritis and
Rheumatism, 32(6), 370–377. https://doi.org/10.1053/sarh.2002.50003
15. Li, Y.-T., Guo, Y.-X., Cai, L.-M., Pan, L., Duan, M.-Q., Yang, L.-F., Sun, Y.-Y., Tan, W.-P., & Chen, Z.-G. (2017). Methylprednisolone pulse
therapy rescued life-threatening pulmonary hemorrhage due to idiopathic pulmonary hemosiderosis. The American Journal of
Emergency Medicine, 35(11), 1786.e3-1786.e7. https://doi.org/10.1016/j.ajem.2017.07.094
16. Möckel, T., Basta, F., Weinmann-Menke, J., & Schwarting, A. (2021). B cell activating factor (BAFF): Structure, functions, autoimmunity and
clinical implications in Systemic Lupus Erythematosus (SLE). Autoimmunity Reviews, 20(2), 102736. https://doi.org/10.1016/j.autrev.2020.102736
17. Parker, B., & Bruce, I. N. (2019). 49—Clinical Markers, Metrics, Indices, and Clinical Trials. In D. J. Wallace & B. H. Hahn (Eds.), Dubois’
Lupus Erythematosus and Related Syndromes (Ninth Edition) (pp. 614–630). Elsevier. https://doi.org/10.1016/B978-0-323-47927-1.00049-9
18. Yan, S., Deng, X., Wang, Q., Sun, X., & Wei, W. (2015). Prednisone treatment inhibits the differentiation of B lymphocytes into plasma cells in MRL/MpSlac-lpr mice. Acta Pharmacologica Sinica, 36(11), 1367–1376. https://doi.org/10.1038/aps.2015.76
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.